DOCSLIB.ORG

Mechanistic Comparison Between MPTP and Rotenone Neurotoxicity in Mice T ⁎ Sunil Bhurtel, Nikita Katila, Sunil Srivastav, Sabita Neupane, Dong-Young Choi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanistic Comparison Between MPTP and Rotenone Neurotoxicity in Mice T ⁎ Sunil Bhurtel, Nikita Katila, Sunil Srivastav, Sabita Neupane, Dong-Young Choi Neurotoxicology 71 (2019) 113–121 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Full Length Article Mechanistic comparison between MPTP and rotenone neurotoxicity in mice T ⁎ Sunil Bhurtel, Nikita Katila, Sunil Srivastav, Sabita Neupane, Dong-Young Choi Yeungnam University, 280 Daehak-Ro, Gyeongsan, Gyeongbuk, 38541, Republic of Korea ARTICLE INFO ABSTRACT Keywords: Animal models for Parkinson’s disease (PD) are very useful in understanding the pathogenesis of PD and MPTP screening for new therapeutic approaches. 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and rotenone Rotenone are common neurotoxins used for the development of experimental PD models, and both inhibit complex I of ’ Parkinson s disease mitochondria; this is thought to be an instrumental mechanism for dopaminergic neurodegeneration in PD. In Neurotrophic factors this study, we treated mice with MPTP (30 mg/kg/day) or rotenone (2.5 mg/kg/day) for 1 week and compared the neurotoxic effects of these toxins. MPTP clearly produced dopaminergic lesions in both the substantia nigra and the striatum as shown by loss of dopaminergic neurons, depletion of striatal dopamine, activation of glial cells in the nigrostriatal pathway and behavioral impairment. In contrast, rotenone treatment did not show any significant neuronal injury in the nigrostriatal pathway, but it caused neurodegeneration and glial activation only in the hippocampus. MPTP showed no such deleterious effects in the hippocampus suggesting the higher susceptibility of the hippocampus to rotenone than to MPTP. Interestingly, rotenone caused upregulation of the neurotrophic factors and their downstream PI3K-Akt pathway along with adenosine monophosphate-activated protein kinase (AMPK) activation. These results suggest that MPTP-induced dopaminergic neurotoxicity is more acute and specific in comparison to rotenone toxicity, and compensatory brain-derived neurotrophic factor (BDNF) induction and AMPK activation in the rotenone-treated brain might suppress the neuronal injury. 1. Introduction mitochondrial forms and functions (Greenamyre et al., 1999; Moon and Paek, 2015). Death of neurons occurs mostly via a reduction in mi- Parkinson’s disease (PD) is the second most common neurodegen- tochondrial complex I enzyme activity leading to ATP depletion, gen- erative disorder after Alzheimer’s disease, affecting 0.5–1% of the el- eration of ROS, and activation of caspase 3 (Greenamyre et al., 1999; derly population (Aguirre-Vidal et al., 2015). Apart from 10% of cases Martinez and Greenamyre, 2012). reported as familial PD, the rest of the cases are sporadic or idiopathic Environmental neurotoxins are utilized widely to recapitulate the with no known causes (Cannon et al., 2009; Le et al., 2014). PD is a symptoms and pathology of PD in experimental animals (Cannon et al., progressive neurodegenerative disease characterized by a profound loss 2009; Fleming et al., 2004). MPTP and rotenone are two of such well- of dopamine-producing neurons of the midbrain (specifically of the known neurotoxins. Both MPTP and rotenone have the ability to cross basal ganglia) along with death of several non-dopaminergic neurons the blood brain barrier due to their high lipophilicity (Tieu, 2011). resulting in its reclassification as a multicentric disease (Cicchetti et al., MPTP requires metabolism by the astroglial cells into its active meta- 2009; Johnson and Bobrovskaya, 2015). Some of the well-known and bolite 1-methyl-4-phenyl pyridinium (MPP+) before entering specifi- important mechanisms in the pathogenesis of PD are aging, mi- cally into dopaminergic neurons through dopamine transporters, tochondrial defects accompanied by oxidative stress, neuroinflamma- whereas rotenone needs no metabolism or transporters to enter neurons tion, disturbed proteostasis, and calcium mishandling (Andersen and (Giordano et al., 2012; Nopparat et al., 2014). These toxins inhibit the Chinta, 2016; Moon and Paek, 2015; Schapira et al., 1990). mitochondrial complex I activity thereby increasing oxidative stress Mitochondria, that are an integral part of all eukaryotic cells, are and are widely utilized in rodents and other species for mimicking involved in the production of energy via the respiratory chain, reg- experimental PD (Angelova and Abramov, 2018). ulation of cell death, calcium metabolism and production of reactive The MPTP model is the most commonly used animal model of PD, oxygen species (ROS). Deficiency of systemic mitochondrial complex I but the major limitation is the inability to produce progressive neuro- is involved in the pathogenesis of idiopathic PD as denoted by aberrant degeneration and Lewy body pathology (Le et al., 2014; Schober, ⁎ Corresponding author at: College of Pharmacy, Yeungnam University, 280 Daehak-Ro, Gyeongsan, Gyeongbuk, 38541, Republic of Korea. E-mail addresses: [email protected] (S. Bhurtel), [email protected] (N. Katila), [email protected] (S. Srivastav), [email protected] (S. Neupane), [email protected] (D.-Y. Choi). https://doi.org/10.1016/j.neuro.2018.12.009 Received 27 September 2018; Received in revised form 24 December 2018; Accepted 28 December 2018 Available online 31 December 2018 0161-813X/ © 2019 Elsevier B.V. All rights reserved. S. Bhurtel et al. Neurotoxicology 71 (2019) 113–121 2004). Rotenone on the other hand has been shown to induce phos- 2.3. Western blot analysis phorylation and aggregation of α-synuclein, Lewy body-like pathology, DJ-1 acidification and translocation, proteasomal dysfunction and ni- Brain tissue samples were homogenized with ice-cold NP-40 lysis gral iron accumulation which are cardinal pathologic changes in the buffer [0.15 M NaCl, 1% NP-40, 0.05 M Tris (pH 8.0), and 1% protease brains of patients with PD (Cannon et al., 2009; Duty and Jenner, 2011; inhibitor cocktail (Thermo Fisher Scientific Inc.)]. The tissue homo- Johnson and Bobrovskaya, 2015). Despite its great potential, the main genates were centrifuged at 4 °C for 20 min at 13,000 g, and the su- problem with this toxin has been its systemic toxicity leading to high pernatant was transferred to a fresh tube. Protein concentration was morbidity and mortality. Also, lower doses either fail or cause highly determined using a BCA protein assay kit (Thermo Fisher Scientific variable loss of dopaminergic neurons (Vingill et al., 2017). Some of the Inc.). Equal amount of protein (30∼40 μg) was mixed with loading other limitations of this model are the location and distribution of the buffer (0.125 M Tris−HCl, pH 6.8, 20% glycerol, 4% sodium dodecyl lesions within the striatum, the magnitude of the lesions and neuro- sulfate (SDS), 10% mercaptoethanol, and 0.002% bromophenol blue) chemical deficits (Wrangel et al., 2015). These issues have been over- and boiled for 7 min to induce denaturation of proteins. The samples come to some extent by using different routes of administration were separated on 12% SDS-polyacrylamide gel by electrophoresis and (Johnson and Bobrovskaya, 2015). transblotted to polyvinylidene difluoride membranes (Millipore In this investigation, we analyzed the difference between the sub- Corporation, Temecula, CA). Membranes were blocked using 5% chronic effects of MPTP and rotenone on the behavioral, neurochem- skimmed milk in Tris-buffered saline (0.1% Tween 20, TBST), for 1 h. ical, immunohistological, and biochemical parameters. This study dis- To detect phospho-proteins, the membrane was blocked in 5% bovine plays that MPTP neurotoxicity is more specific and acute than rotenone serum albumin in TBST. Then, the membrane was incubated overnight toxicity, and induction of neurotrophic factor and AMP-activated pro- at 4 °C with specific primary antibodies against BDNF (1:2000; Santa tein kinase (AMPK) activation may be related to the minimal effects of Cruz), GDNF (1:2000, Abcam), AMPK (1:2000; Cell Signaling rotenone on the biochemical physiology of the brain. Intriguingly, ro- Technology), p-AMPK (1:2000; Cell Signaling Technology), phosphati- tenone induced degeneration of the hippocampal neurons to some ex- dylinositol-3 kinase (PI3K; 1:2000, Cell Signaling Technology), p-PI3K tent. (1:2000, Cell Signaling Technology), protein kinase B (Akt; 1:2000; Cell Signaling Technology), p-Akt (1:2000; Cell Signaling Technology), β- actin (1:10,000; Ab-Frontier), and GAPDH (1:10,000; Ab-Frontier). 2. Materials and methods After being washed thrice with TBST, the membrane was incubated with a secondary antibody for 1 h at room temperature and again wa- 2.1. Animals and treatment of toxins shed thrice with TBST. Finally, the membrane was incubated with en- hanced chemiluminescence reagents (Thermo Scientific Inc.) and ex- Adult (10-week-old) male C57BL/6 mice (20–25 g, Japan SLC, Inc.) posed in a luminescence image analyzer (Fusion Solo, VilberLourmat, were housed in microisolator cages on a 12 h light/dark cycle with free France) to detect the immunoreactive complex. The density of each blot access to food and water. After 1 week of acclimatization, the mice were was assessed using GelQuant.Net software. divided into different groups. Animal experiments were performed according to the protocol ap- 2.4. Behavioral tests proved by the IACUC of Yeungnam University before the study (ap- proval number: 2016-004). All animal experiments complied with the Behavioral tests were carried out on Day 0 and 5 to evaluate the ARRIVE guidelines and were carried out in accordance with the motor deficits in the MPTP and rotenone-intoxicated animals.
Load more

Recommended publications
  • 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Hydrochloride (M0896)
    1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Product Number M 0896 Store at Room Temperature Product Description References 1. The Merck Index, 12th ed., Entry# 6376. Molecular Formula: C12H15N • HCl 2. Przedborski, S., et al., The parkinsonian toxin Molecular Weight: 209.7 MPTP: action and mechanism. Restor. Neurol. CAS Number: 23007-85-4 Neurosci., 16(2), 135-142 (2000). Synonym: MPTP • HCl 3. Adams, J. D., Jr., et al., Parkinson's disease - redox mechanisms. Curr. Med. Chem., 8(7), 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 809-814 (2001). is a piperidine derivative and dopaminergic neurotoxin 4. Ziering, A., et al., Piperidine Derivatives. Part III. that has been used in neurological research. MPTP is 4-Arylpiperidines. J. Org. Chem., 12, 894-903 metabolized to 1-methyl-4-phenylpyridine (MPP+), (1947). which in turn can cause free radical production in vivo 5. Schmidle, C. J., and Mansfield, R. C, The and lead to oxidative stress. Thus MPP+ is generally aminomethylation of olefins. IV. The formation of acknowledged as the active metabolite derived from 1-alkyl-4-aryl-1,2,3,6-tetrahydropyridines. J. Am. MPTP.2,3 The synthesis of MPTP has been Chem. Soc., 78, 425-428 (1956). reported.4,5 6. Davis, G. C., et al., Chronic Parkinsonism secondary to intravenous injection of meperidine MPTP is widely utilized in in vivo research studies as a analogues. Psychiatry Res., 1, 249-254 (1979). model for Parkinsonism.6-11 A mouse investigation of 7. Burns, R. S., et al., A primate model of MPTP treatment has indicated a possible role for parkinsonism: selective destruction of cyclooxygenase 2 (COX-2) in Parkinsonian dopaminergic neurons in the pars compacta of the neurodegeneration.12 A review describes the substantia nigra by N-methyl-4-phenyl-1,2,3,6- application of MPTP studies to programmed cell death tetrahydropyridine.
    [Show full text]
  • Ecstasy: the Clinical, Pharmacological and Neurotoxicological Effects of the Drug Mdma Topics in the Neurosciences
    ECSTASY: THE CLINICAL, PHARMACOLOGICAL AND NEUROTOXICOLOGICAL EFFECTS OF THE DRUG MDMA TOPICS IN THE NEUROSCIENCES Other books in the series: Rahamimoff, Rami and Katz, Sir Bernard, eds.: Calcium, Neuronal Function and Transmitter Release. ISBN 0-89838-791-4. Fredrickson, Robert C.A., ed.: Neuroregulation of Autonomic, Endocrine and Immune Systems. ISBN 0-89838-800-7. Giuditta, A., et al., eds.: Role of RNA and DNA in Brain Function. ISBN 0-89838-814-7. Stober, T., et al.,: Central Nervous System Control of the Heart. ISBN 0-89838-820-l. Kelly J., et al., eds.: Polyneuropathies Associated with Plasma Cell Dyscrasias. ISBN 0-89838-884-8. Galjaard, H. et al., eds.: Early Detection and Management of Cerebral Palsy. ISBN 0-89838-890-2. Ferrendelli, J., et al., eds.: Neurobiology of Amino Acids, Pep tides and Trophic Factors. ISBN 0-89838-360-9. ECSTASY: THE CLINICAL, PHARMACOLOGICAL AND NEUROTOXICOLOGICAL EFFECTS OF THE DRUGMDMA Edited by STEPHEN J. PEROUTKA Stanford University Medical Center ~. KLUWER ACADEMIC PUBLISHERS "BOSTON IDORDRECHT ILONDON Distributors for North America: Kluwer Academic Publishers, 101 Philip Drive, Assinippi Park, Norwell, MA, 02061, USA for all other countries: Kluwer Academic Publishers Group, Distribution Centre, Post Office Box 322, 3300 AH Dordrecht, The Netherlands Library of Congress Cataloging-in-Publication Data Ecstasy: the clinical, pharmacological, and neurotoxicological effects of the drug MDMA / edited by Stephen]. Peroutka. p. cm. - (Topics in the neurosciences; TNSC9) Includes bibliographies and index. ISBN- 13:978- I -4612-8799-5 e-ISBN-13:978- I -4613-1485-1 DOl: 10.1007/978-1-4613-1485-1 1. MDMA (Drug) 2.
    [Show full text]
  • Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates
    The Journal of Neuroscience, October 8, 2003 • 23(27):9107–9115 • 9107 Behavioral/Systems/Cognitive 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates Mahmoud M. Iravani, Michael J. Jackson, Mikko Kuoppama¨ki, Lance A. Smith, and Peter Jenner Neurodegenerative Disease Research Centre, Guy’s, King’s, and St. Thomas’ School of Biomedical Sciences, King’s College, London SE1 1UL, United Kingdom Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] was shown to prolong the action of L-3,4-dihydroxyphenylalanine (L-DOPA) while suppressing dyskinesia in a single patient with Parkinson’s disease (PD). The clinical basis of this effect of MDMA is unknown but may relate to its actions on either dopaminergic or serotoninergic systems in brain. In normal, drug-naive common marmosets, MDMA administration suppressed motor activity and exploratory behavior. In 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-treated, L-DOPA-primedcommonmarmosets,MDMAtransientlyrelievedmotordisability but over a period of 60 min worsened motor symptoms. When given in conjunction with L-DOPA, however, MDMA markedly decreased dyskinesia by reducing chorea and to a lesser extent dystonia and decreased locomotor activity to the level observed in normal animals. MDMA similarly alleviated dyskinesia induced by the selective dopamine D2/3 agonist pramipexole. The actions of MDMA appeared to be mediated through 5-HT mechanisms because its effects were fully blocked by the selective serotonin reuptake inhibitor fluvoxamine. Furthermore,theeffectofMDMAon L-DOPA-inducedmotoractivityanddyskinesiawaspartiallyinhibitedby5-HT1a/bantagonists.The ability of MDMA to inhibit dyskinesia results from its broad spectrum of action on 5-HT systems.
    [Show full text]
  • Designer-Drugs-China-White-And-MPTP.Pdf
    Selected Papers of William L. White www.williamwhitepapers.com Collected papers, interviews, video presentations, photos, and archival documents on the history of addiction treatment and recovery in America. Citation: White, W. (2014). Designer drugs, China white, and the story of MPTP. Posted at www.williamwhitepapers.com Designer Drugs, China White, and the Story of MPTP William L. White Emeritus Senior Research Consultant Chestnut Health Systems [email protected] NOTE: The original 1,000+ page manuscript for Slaying the Dragon: The History of Addiction Treatment and Recovery in America had to be cut by more than half before its first publication in 1998. This is an edited excerpt that was deleted from the original manuscript. "Designer drugs"--a term coined by The modern story of designer drugs pharmacologist Gary Henderson, of the begins in 1976 with Barry, a bright, twenty- University of California--represent efforts by three-year-old college student from chemists to alter the molecular structure of a Bethesda, Maryland. Barry created an psychoactive drug to change the drug analogue of meperidine (Demerol)--MPPP, identity while maintaining or intensifying the that was not legally controlled as a way to original drug's psychoactive properties. avoid contact with the illicit drug market. He Designer drugs are often analogues-- continued to synthesize and use MPPP for chemical cousins--of the drugs they’re six months without incident. In the summer modeled after and may have effects and of 1976, he made a new batch of MPPP but risks quite different than these original through a mistake in the synthesis procedure substances.
    [Show full text]
  • Signaling Plays an Important Role in MPTP-Induced Neuronal Death
    Cell Death and Differentiation (2016) 23, 542–552 & 2016 Macmillan Publishers Limited All rights reserved 1350-9047/16 www.nature.com/cdd c-Abl–p38α signaling plays an important role in MPTP-induced neuronal death RWu1,2, H Chen1,3,JMa1,2,QHe1,2, Q Huang4, Q Liu5, M Li*,4 and Z Yuan*,1,2,3 Oxidative stress is a major cause of sporadic Parkinson’s disease (PD). Here, we demonstrated that c-Abl plays an important role in oxidative stress-induced neuronal cell death. C-Abl, a nonreceptor tyrosine kinase, was activated in an 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine hydrochloride (MPTP)-induced acute PD model. Conditional knockout of c-Abl in neurons or treatment of mice with STI571, a c-Abl family kinase inhibitor, reduced the loss of dopaminergic neurons and ameliorated the locomotive defects induced by short-term MPTP treatment. By combining the SILAC (stable isotope labeling with amino acids in cell culture) technique with other biochemical methods, we identified p38α as a major substrate of c-Abl both in vitro and in vivo and c-Abl- mediated phosphorylation is critical for the dimerization of p38α. Furthermore, p38α inhibition mitigated the MPTP-induced loss of dopaminergic neurons. Taken together, these data suggested that c-Abl–p38α signaling may represent a therapeutic target for PD. Cell Death and Differentiation (2016) 23, 542–552; doi:10.1038/cdd.2015.135; published online 30 October 2015 Parkinson’s disease (PD), the second most common neuro- cell signaling activities, including growth factor signaling, cell degenerative disorder,
    [Show full text]
  • Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration
    8138 • The Journal of Neuroscience, July 25, 2007 • 27(30):8138–8148 Neurobiology of Disease Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration W. Michael Caudle,1,2 Jason R. Richardson,1,2,3 Min Z. Wang,1,2 Tonya N. Taylor,1,2 Thomas S. Guillot,1,2 Alison L. McCormack,4 Rebecca E. Colebrooke,5 Donato A. Di Monte,4 Piers C. Emson,5 and Gary W. Miller1,2 1Center for Neurodegenerative Disease, 2Department of Environmental and Occupational Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, 3Department of Environmental and Occupational Medicine, University of Medicine and Dentistry-New Jersey/Robert Wood Johnson Medical School and Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey 08854, 4The Parkinson’s Institute, Sunnyvale, California 94089, and 5The Babraham Institute, Neurobiology Programme, Babraham, Cambridge CB2 4AT, United Kingdom The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is responsible for packaging dopamine into vesicles for subsequent release and has been suggested to serve a neuroprotective role in the dopamine system. Here, we show that mice that express ϳ5% of normal VMAT2 (VMAT2 LO) display age-associated nigrostriatal dopamine dysfunction that ultimately results in neurodegeneration. Elevated cysteinyl adducts to L-DOPA and DOPAC are seen early and are followed by increased striatal protein carbonyl and 3-nitrotyrosine formation. These changes were associated with decreased striatal dopamine and decreased expression of the dopamine transporter and tyrosinehydroxylase.Furthermore,weobservedanincreasein␣-synucleinimmunoreactivityandaccumulationandneurodegeneration in the substantia nigra pars compacta in aged VMAT2 LO mice. Thus, VMAT2 LO animals display nigrostriatal degeneration that begins in the terminal fields and progresses to eventual loss of the cell bodies, ␣-synuclein accumulation, and an L-DOPA responsive behavioral deficit, replicating many of the key aspects of Parkinson’s disease.
    [Show full text]
  • Exposure of Mice to Tobacco Smoke Attenuates the Toxic Effect of Methamphetamine on Dopamine Systems
    Toxicology Letters 118 (2000) 43–46 www.elsevier.com/locate/toxlet Exposure of mice to tobacco smoke attenuates the toxic effect of methamphetamine on dopamine systems Stephen C. Bondy a,*, Syed F. Ali b, Michael T. Kleinman a a Center for Occupational and En6ironmental Health, Department of Community and En6ironmental Medicine, Uni6ersity of California, Ir6ine, CA 92697-1820, USA b Di6ision of Neurotoxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA Received 26 May 2000; received in revised form 28 August 2000; accepted 29 August 2000 Abstract Methamphetamine treatment of mice rapidly and severely depleted levels of dopamine and its metabolites, homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) in the caudate nucleus. Exposure of mice to cigarette smoke by means of nose-only breathing apparatus for 20 min twice daily over 3 days prior to drug treatment significantly attenuated the neurotoxicity of methamphetamine as judged by a lesser depletion of dopamine, DOPAC and HVA. The lesser effect of methamphetamine upon content of serotonin level was unaltered by prior inhalation of smoke. Results suggest a specific protective effect of inhaled tobacco smoke upon the effects of methamphetamine upon dopaminergic circuitry. © 2000 Elsevier Science Ireland Ltd. All rights reserved. Keywords: Tobacco smoke; Nicotine; Methamphetamine; Dopamine; Cigarettes; Parkinson’s disease 1. Introduction 1999). Environmental factors may contribute to- ward the incidence of Parkinson’s disease (PD) There are several reports concerning the protec- (Langston, 1998), and MPTP and metham- tive properties of nicotine upon the dopaminergic phetamine provide useful animal models for some system following its exposure to specific toxins. aspects of this neurodegenerative disorder.
    [Show full text]
  • KDS2010, a Newly Developed Reversible MAO-B Inhibitor, As an Effective Therapeutic Candidate for Parkinson’S Disease
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190579; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s disease Min-Ho Nam1†, Jong-Hyun Park2†, Hyo Jung Song2†, Ji Won Choi2, Siwon Kim2,3, Bo Ko Jang2, Hyung Ho Yoon4, Jun Young Heo1,5, Doo-Wan Cho6, Young-Su Yang6, Su-Cheol Han6, Sangwook Kim7, Soo-Jin Oh1, Sang Ryong Jeon4, Ki Duk Park2,3*, C. Justin Lee1,8* 1Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea, 2Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, KIST, Seoul 02792, Republic of Korea, 3Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792 Republic of Korea, 4Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 5Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea, 6Jeonbuk Branch Institute, Korea Institute of Toxicology, Jeonbuk 56212, Republic of Korea, 7Neurobiogen, Gyeonggi- do 13201, Republic of Korea, 8Center for Cognition and Sociality, Institute for Basic Science, Daejeon 34126, Republic of Korea, Republic of Korea * To whom correspondence should be addressed. Ki Duk Park, TEL: +82-2-958-5132; FAX: +82-2-958-6999; E-mail: [email protected] C. Justin Lee, TEL: +82-42-878-9150; FAX: +82-42-878-9151; E-mail: [email protected] Running Title: KDS2010 for Parkinson’s disease Keywords: MAO-B inhibitor; MPTP; Reactive glia; Parkinson’s disease 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.06.190579; this version posted July 7, 2020.
    [Show full text]
  • Mechanisms of Vesicular Monoamine Transporter-2 Degradation
    MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION by Erin Kathleen Stachowski B.A., University of Rochester, 2006 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2016 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Erin Kathleen Stachowski It was defended on November 7, 2016 and approved by Edda Thiels, PhD, Associate Professor, Dept. Neurobiology Alexander Sorkin, PhD, Professor, Dept. Cell Biology Jeffrey Brodsky, PhD, Professor, Dept. Biological Sciences Teresa Hastings, PhD, Associate Professor, Dept. Neurology Habibeh Khoshbouei, PharmD, PhD, Associate Professor, Univ. Florida, Dept. Neuroscience Dissertation Advisor: Gonzalo Torres, PhD, Associate Professor, Univ. Florida, Dept. Pharmacology and Therapeutics ii Copyright © by Erin Kathleen Stachowski 2016 iii MOLECULAR MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION Erin Kathleen Stachowski, PhD University of Pittsburgh, 2016 The vesicular monoamine transporter-2 (VMAT2) packages monoamines into synaptic vesicles in the central nervous system. Not only vital for monoaminergic neurotransmission, VMAT2 protects neurons from cytosolic dopamine-related toxicity by sequestering dopamine into vesicles. This dissertation research is focused on determining the basic mechanisms of VMAT2 degradation—an unexplored aspect of VMAT2 regulation. The processes of protein synthesis and degradation balance to maintain proteostasis. As VMAT2 availability and function directly impact monoamine neurotransmission, its degradation is an important aspect of VMAT2 maintenance to study. While it has been proposed that VMAT2 is degraded by the lysosome, an acidic membrane-bound organelle, there is no direct evidence demonstrating this. In a PC12 cell model system stably expressing VMAT2-GFP, pharmacological tools were used to determine the impact of inhibiting pieces of cellular degradation machinery (the lysosome or the 26S proteasome) on VMAT2.
    [Show full text]
  • Mptp Is Used
    PLEASE POST THIS SUMMARY IN AREAS WHERE MPTP IS USED UNIVERSITY OF CALIFORNIA SAN FRANCISCO ENVIRONMENT, HEALTH AND SAFETY/BIOSAFETY MPTP EXPOSURE/INJURY RESPONSE PROTOCOL FOR USE IN RESEARCH LABORATORIES Organism or Agent: MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) Exposure Risk: Parkinson’s Disease like syndrome UCSF Occupational Health Services: 415/885-7580 (Available during work hours) Office of Environment, Health & Safety: 415/476-1300 (Main number; available during work hours) 415/476-1414 or 9-911 (In case of emergency, via the UCSF Police Department; available 24 hours) EH&S Public Health Officer: 415/476-1722 Biosafety Officer: 415/514 - 2824 Exposure Hotline: 415/353-7842 (Available 24 hours) ______________________________________________________________________________________ PROTOCOL SUMMARY In the event of an accidental exposure or injury, the protocol is as follows: 1. Modes of Exposure: • High Risk Exposures a. Skin puncture or injection b. Ingestion of MPTP c. Inhalation of MPTP powder d. Contact with mucous membranes (eyes, nose, mouth) e. Contact with non-intact skin • Low Risk/Potential Exposure: a. Contact with animal bedding within 72 hours of animal exposure to MPTP b. Percutaneous contact with body fluids from a recently exposed animal c. Contact with intact skin 2. Immediate First Aid: • Skin Exposure: Immediately go to the sink and thoroughly wash the wound with soap and water for 10-15 minutes. • Skin Wound: Immediately go to the sink and thoroughly wash the wound with soap and water for 3 minutes then pat dry. If possible, continue to wash for 10-15 minutes while calling the Exposure Hotline, 415/353-7842, or go to the Emergency Department in case of severe injury.
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]
  • Characterization of Vesicular Monoamine Transporter 2 and Its Role in Parkinson's Disease Pathogenesis Using Drosophila Antonio Joel Tito Jr
    Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 12-2016 Characterization of Vesicular Monoamine Transporter 2 and its role in Parkinson's Disease Pathogenesis using Drosophila Antonio Joel Tito Jr. Sheng Zhang Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Cell Biology Commons, Medicine and Health Sciences Commons, Molecular and Cellular Neuroscience Commons, Molecular Biology Commons, and the Molecular Genetics Commons Recommended Citation Tito, Antonio Joel Jr. and Zhang, Sheng, "Characterization of Vesicular Monoamine Transporter 2 and its role in Parkinson's Disease Pathogenesis using Drosophila" (2016). UT GSBS Dissertations and Theses (Open Access). 719. http://digitalcommons.library.tmc.edu/utgsbs_dissertations/719 This Dissertation (PhD) is brought to you for free and open access by the Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in UT GSBS Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. CHARACTERIZATION OF VESICULAR MONOAMINE TRANSPORTER 2 AND ITS ROLE IN PARKINSON’S DISEASE PATHOGENESIS USING DROSOPHILA By Antonio Joel Tito Jr., M.S. APPROVED: _______________________ Sheng Zhang, Ph.D. _______________________ Hugo Bellen, Ph.D. _______________________ Richard Behringer, Ph.D. _______________________ Kartik Venkatachalam, Ph.D. _______________________ Momiao Xiong, Ph.D. _______________________ Nick Justice, Ph.D. _______________________ Andrew Bean, Ph.D. APPROVED: _______________________ Dean, UTHealth Graduate School of Biomedical Sciences at Houston CHARACTERIZATION OF VESICULAR MONOAMINE TRANSPORTER 2 AND ITS ROLE IN PARKINSON’S DISEASE PATHOGENESIS USING DROSOPHILA A DISSERTATION Presented to the Faculty of The University of Texas Health Science Center at Houston And The University of Texas M.D.
    [Show full text]